Grounded in science, elevating the standard
We are a global cannabinoid company, committed to growth through scientific innovation and operational integrity.
TerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, TerrAscend participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use. TerrAscend was the first cannabis company with sales in the US, Canada, and Europe. TerrAscend operates a number of synergistic businesses, including The Apothecarium, an award-winning cannabis dispensary with several retail locations in California; Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products; Ilera Healthcare, Pennsylvania’s premier medical marijuana cultivator, processor and dispenser; and Valhalla Confections, a manufacturer of premium cannabis-infused edibles. TerrAscend holds a cultivation permit in the State of New Jersey and is pending approval for a vertically integrated medical cannabis operation with the ability to operate up to 3 Alternative Treatment Centers. Additionally, TerrAscend holds a Medical Cannabis Processor License in the State of Utah.
Executive Leadership Team
Mr. Stauffer has over 25 years of experience as a business executive holding various senior finance and leadership roles across multiple industries. Most recently, Mr. Stauffer served as Senior Vice President of Finance and Chief Financial Officer of the Global Consumer Beauty Division at Coty, Inc. Prior to his role at Coty, Mr. Stauffer spent 10 years at The Hershey Company holding various senior financial positions, including Vice President of Finance and Chief Financial Officer for Hershey’s International business, leading Corporate FP&A and Internal Audit. Prior to Hershey, Mr. Stauffer held various finance positions, both domestically and internationally, at Dell Technologies and Procter & Gamble.
Jason has more than two decades of legal experience and over a decade of global experience. He has served in a variety of functions for multi-national companies in life sciences, including biotechnology, pharmaceuticals, consumer health, and medical devices.
Most recently, Mr. Marks served as the Chief Legal Officer, General Counsel & Corporate Secretary of InflaRx N.V., a publicly traded biotechnology company. In this role, he was a member of the executive management team responsible for all aspects of legal, compliance, and corporate governance, as well as driving key business and strategic initiatives. Mr. Marks was also responsible for the operations of the company’s U.S. subsidiary.
Prior to his role at InflaRx, Mr. Marks was SVP, Head of Legal Branded Rx (Salix) and Global Litigation & Government Investigations, at Bausch Health, where he managed some of the highest-profile matters in life sciences, was the lead lawyer for Salix, a $2B division of Bausch Health, and created and led the company’s first Legal Operations and Enterprise Risk Management functions. Mr. Marks also held senior roles at Novartis’s Alcon division, including the head of legal for North America and at Stryker Corporation. Mr. Marks received a J.D. from The George Washington University School of Law and an A.B. in History from The University of Chicago.
Joanna has over 12 years of human resources, operational execution and strategic leadership experience within retail and manufacturing sectors. She has worked extensively with investment professionals of private equity in leading change management in M & As, execution of multi-faceted strategic growth, talent acquisition, policies and governance. A strong partner, who values the importance of the individual as well the team fostering development through strong, meaningful strategies.
Board of Directors
Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, and the advisor for five investment partnerships with over $2 billion in assets under management. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the healthcare sector. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy. Mr. Wild is the Chairman of the Board of TerrAscend Corp. and Arbor Pharmaceuticals. He is a board member of Vensun Pharmaceuticals and Vitruvias Therapeutics. Funds managed by JW Asset Management, LLC are the largest shareholders in TerrAscend Corp. Mr. Wild is also a board member of NETA NJ LLC where he will be actively involved in planning and directing the organization’s strategic and long-range goals.
Richard Mavrinac held positions as CFO for George Weston Limited and Executive VP of Loblaw Companies and has extensive expertise in public company finance and strategy.
Craig Collard is the CEO of Veloxis Pharmaceuticals, a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patient and has over 20 years of experience in the pharmaceutical industry. Mr. Collard has a proven track-record of leadership, managing organizational change, and driving successful merger and acquisition activity. Prior to Veloxis, Mr. Collard was the Founder and CEO of Cornerstone Therapeutics, a company focused on hospital, respiratory and adjacent specialty markets.
Lisa has 20+ years of experience in manufacturing, distribution, and retail, previously holding senior financial positions with some of Canada’s largest publicly-traded corporations. A strategic thinker with diverse experience in leading growth, Lisa has advised mid-market privately held companies in both the United States and Canada. Lisa holds a BA (Economics) from Western University, and an MBA from Queen’s University, and also holds the Institute of Corporate Directors ICD.D (Certified Director) designation.
Ed Schutter is a seasoned executive with over thirty years of pharmaceutical industry experience. He currently serves as Chief Executive Officer of Arbor Pharmaceuticals (“Arbor”), an Atlanta, Georgia based specialty pharmaceutical company which markets prescription products for the cardiovascular, neuroscience and orphan/hospital markets. Arbor also has several branded prescription products in late stage development. Prior to joining Arbor, Mr. Schutter served as President of Sciele (Shionogi) Pharmaceuticals. Prior to Sciele, he served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. He has also held several senior management roles at the U.S. subsidiary of Solvay during his twenty years with the organization. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, GA. Mr. Schutter is a registered pharmacist with a degree in Pharmaceutical Sciences from Mercer University and an MBA from Kennesaw State University. He is currently a board member of Arbor, Vitruvias Therapeutics, and Establishment Labs (ESTA) and has been a previous board member of other public, private and non profit organizations.
Press Releases & News
|Clarus Securities||Noel Atkinson, CFA||(416) email@example.com|
|ATB Capital Markets||Kenric S. Tyghe||(416) firstname.lastname@example.org|
|Craig-Hallum||Eric Des Lauriers, CFA||(617) email@example.com|
|Ladenburg Thalmann||Glenn G. Mattson||(212) firstname.lastname@example.org|
|Stifel | GMP||Andrew Partheniou||(514) email@example.com|
|Needham & Company, LLC||Matt McGinley||(212) firstname.lastname@example.org|
|Beacon Securities Limited||Russell Stanley||(416) email@example.com|
|Echelon Capital Markets||Andrew Semple, CFA||(416) firstname.lastname@example.org|
|Cantor Fitzgerald||Pablo Zuanic||(212) email@example.com|
|Cowen||Vivien Azer||(646) firstname.lastname@example.org|
Jason Ackerman is scheduled to participate in a fireside chat on January 14, 2021 at 2:45 p.m. ET. Management will also host one-on-one meetings with investors throughout the conference.
Date: January 14, 2021
To Watch Replay: Click Here
Date: January 11-14, 2021
Two days of informative fireside chats with 16 of the leading U.S. Multi-State Operators discussing regulatory changes, company strategies, and discussions about the Cannabis industry.
Date: December 16, 2020
Cowen’s 3rd Annual Boston Cannabis Conference is a virtual event taking place November 30-December 2, 2020. The conference incorporates innovative panel discussions hosted by members of the Cowen research team that focus on first-hand updates on both marketed and emerging products across the spectrum of the cannabis industry.
Date: November 30 – December 2, 2020
Date: September 30, 2020
Replay: Click Here
Date: September 29, 2020
Date: September 10, 2020
Date: August 26, 2020
Date: August 25, 2020
Date: May 29, 2020
Replay: (416) 764-8677 or (888) 390-0541
Replay Code: 330066
Available until 12:00 midnight Eastern Time Friday, June 12th, 2020
Date: May 12, 2020
Details: Jason Ackerman, CEO and Executive Chairman, presented at Canaccord Genuity’s Global Cannabis Conference.
Date: April 24, 2020
Replay: (416) 746-8677 or (888) 390-0541
Replay Code: 459450
Available until 12:00 midnight Eastern Time Friday, May 8th, 2020
Title: TerrAscend in the News: CNBC Squawk Alley
Date: April 14, 2020
Details: Jason Ackerman, CEO of TerrAscend, spoke with CNBC’s “Squawk Alley” about his new role as permanent CEO of TerrAscend, the cannabis market, as well as supply chain and grocery delivery challenges amid the COVID-19 pandemic.
Date: January 14, 2020
Location: Toronto, ON
Details: Jason Ackerman, Executive Chairman, spoke in a Fireside Chat at 2pm at the AltaCorp/ATB 8th Annual Institutional Investor Conference in Toronto.
Hello! We want to learn about your business, discuss your need for investment and explore opportunities to work together. Please share your non-confidential information on the form below and we’ll be in touch.
Chairman Jason Wild on TerrAscend’s commitment to standardization and quality assurance
The Apothecarium’s CEO Ryan Hudson on choosing TerrAscend as a partner
Heather Molloy, EVP Business Development, on how we think about BD
67,300 sq ft facility strategically located in Mississauga
Premium hydroponic cultivation
Sterile & non-sterile drug compounding capabilities
Lab tested to the highest standards